Study of APG-115 alone or with APG-2575 for certain childhood and adult cancers
Part of Cancer clinical trials.
This study tests two experimental drugs for people with neuroblastoma or other solid tumors that have not responded to standard treatment. APG-115 is given alone or with APG-2575 to see if it can shrink tumors and help patients feel better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 5 years old to receive APG-115 alone, or at least 12 years old to receive the combination.
- Your cancer (neuroblastoma or another solid tumor) must have returned or not responded to usual treatments.
- You should be feeling fairly well physically (a score of 50 or higher on the Karnofsky/Lansky scale).
- Your doctor expects you to live at least 3 more months.
- You must have tumors that can be measured on scans (for neuroblastoma, at least one 'target' lesion).
- You need to be willing to provide a tumor tissue sample (fresh or stored) before starting treatment.
- If you could become pregnant or father a child, you must agree to use effective birth control during the study and for 3 months after.
- You must be able to swallow the study pills.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 study tests whether adding either a targeted drug (lorlatinib) or a radioactive treatment (131I-MIBG) to intensive chemotherapy improves outcomes for children with high-risk neuroblastoma. It may help by aiming at tumor cells more directly alongside standard treatment.
This trial tests a new combination of medicines for children with high-risk neuroblastoma that has not responded to previous treatments. The goal is to see if this combination can help shrink or control the tumor.
This Phase 1 trial tests a new antibody drug (GNC-039) that targets a specific feature found on some cancer cells. It is for adults with solid tumors that have come back or stopped responding to standard treatment, aiming to see safety and early signs of effectiveness.
This trial tests combining two immune-boosting drugs (naxitamab and GM-CSF) with a vitamin-A derivative (isotretinoin) to keep high-risk neuroblastoma in remission after standard treatment. It aims to see if this maintenance treatment helps prevent the cancer from returning.
This trial tests giving a combination of naxitamab, irinotecan, and temozolomide for a longer period to people whose neuroblastoma has come back or hasn't responded to standard treatments. The goal is to see if this approach is safe and effective.
This trial tests a combination of chemotherapy and immunotherapy as a first treatment for children and young adults with high-risk neuroblastoma. The goal is to see if this approach can improve outcomes.
Hear when a new Neuroblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.